BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oikonomou E, Vogiatzi G, Tsalamandris S, Mourouzis K, Siasos G, Lazaros G, Skotsimara G, Marinos G, Vavuranakis M, Tousoulis D. Non-natriuretic peptide biomarkers in heart failure with preserved and reduced ejection fraction. Biomark Med 2018;12:783-97. [PMID: 29865857 DOI: 10.2217/bmm-2017-0376] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Tanase DM, Radu S, Al Shurbaji S, Baroi GL, Florida Costea C, Turliuc MD, Ouatu A, Floria M. Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications. Int J Mol Sci 2019;20:E2629. [PMID: 31142058 DOI: 10.3390/ijms20112629] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
2 Lin JF, Wu S, Juang JJ, Chiang FT, Hsu LA, Teng MS, Cheng ST, Huang HL, Ko YL. Osteoprotegerin and osteopontin levels, but not gene polymorphisms, predict mortality in cardiovascular diseases. Biomark Med 2019;13:751-60. [PMID: 31157557 DOI: 10.2217/bmm-2018-0458] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Pinto G, Colombo B, Autieri A, Foppoli L, Spoladore R, Ardizzone V, Margonato A, Corti A, Fragasso G. Vasostatin-1 as a potential novel circulating biomarker in patients with chronic systolic heart failure: A pilot study. Clin Chim Acta 2021;526:49-54. [PMID: 34973182 DOI: 10.1016/j.cca.2021.12.024] [Reference Citation Analysis]